Verdad Advisers’s Kalaris Therapeutics KLRS Stock Holding History
Bought
Maintained
Sold
Other funds holding KLRS
SL
WT
Verdad Advisers's KLRS Position: Q3 2026 in Review
Verdad Advisers increased its Kalaris Therapeutics (KLRS) stake by 75% in Q3 2026, buying an estimated $232K and bringing the position to 140,232 shares worth $405K. The position accounts for 0.43% of the portfolio, ranked #84.
Verdad Advisers first reported a position in KLRS in Q2 2026 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold KLRS as of Q3 2026.
- Verdad Advisers held 140,232 shares of Kalaris Therapeutics worth $405K as of Q3 2026.
- Verdad Advisers bought 59,935 Kalaris Therapeutics shares in Q3 2026, an estimated $232K.
- Kalaris Therapeutics made up 0.43% of Verdad Advisers's portfolio in Q3 2026, its #84 holding.
- Verdad Advisers first reported a position in Kalaris Therapeutics in Q2 2026 and has held it in 2 quarters since.
- 54 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2026.
Based on Verdad Advisers's 13F filing for Q3 2026, filed 16 Nov 2026.